Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07317440

Coenzyme Q10 in Pediatric Community-Acquired Pneumonia

The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Community Acquired Pneumonia Community-Acquired Infections Community-Acquired Pneumonia Infections Pneumonia Respiratory Tract Diseases Respiratory Tract Infections

Age range

2 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tanta University

Tanta, Gharbia Governorate, 37515, Egypt

Location contact

Ahmed Elniny [email protected], MD

SUB_INVESTIGATOR

Rehab Zaki Elmeazawy

CONTACT

01004815280

Rehab Zaki Elmeazawy, MD

PRINCIPAL_INVESTIGATOR

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia

Exclusion criteria

  • Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.

Treatment and study plan

oral coenzymeQ10

Drug

60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.

Primary outcomes

  1. Normalization of respiratory rate

    Time frame: 3 days

  2. Normalization of temperature

    Time frame: 3 days

  3. Normalization of oxygen saturation

    Time frame: 3 days

  4. Normalization of Feeding Behavior Assessed by Oral Intake Tolerance

    Time frame: 3 days

    Normalization of feeding refusal will be assessed by evaluating the child's ability to tolerate age-appropriate oral feeding without refusal over a 3-day observation period.

  5. Serum C-Reactive Protein (CRP) Level

    Time frame: 5 days

    Blood samples will be collected, and CRP concentration will be expressed in milligrams per liter (mg/L).

  6. Serum Lactate Dehydrogenase (LDH) Level

    Time frame: 5 days

    LDH concentration will be reported in units per liter (U/L) from venous blood samples.

  7. Prognostic Nutritional Index

    Time frame: 5 days

  8. Systemic Immune-Inflammation Index

    Time frame: 5 days

  9. Serum C-Reactive Protein to Albumin Ratio (CRP/Albumin Ratio)

    Time frame: 5 days

    The serum C-reactive protein to albumin ratio (CRP/albumin ratio) will be calculated as a single composite outcome measure using laboratory values obtained from the same blood sample.

  10. Time of clinical stability

    Time frame: 3-5 days

Secondary outcomes

  1. Length of hospital stay

    Time frame: 10-21 days

  2. Number of Participants Requiring Surgical Intervention

    Time frame: 21-30 days

    This outcome measures whether a participant undergoes any surgical intervention related to the study condition during the follow-up period. Surgical intervention is defined as any operative procedure performed under general or regional anesthesia, as documented in the medical record.

    The outcome will be recorded as a binary variable (Yes/No) for each participant and summarized as the number and proportion of participants requiring surgical intervention.

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed Elniny Lecturer of Pediatrics, MD

CONTACT

[email protected]

01002219783

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Coenzyme Q10 as an Adjunct Therapy in Pediatric Community-Acquired Pneumonia

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 5, 2026
Registry last updated
Jan 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.